Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Vaccines
Filter     Order     Display # 
Date Item Title
14 Nov 2008 New Data Points to Long Lasting Beneficial Effects of CEL-SCI's Rheumatoid Arthritis Vaccine
13 Nov 2008 GARDASIL(R), Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
12 Nov 2008 Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
05 Nov 2008 Bavarian Nordic reports successful safety data from Phase II study with IMVAMUNE (R)
04 Nov 2008 MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
03 Nov 2008 Canopus BioPharma Announces Positive Results in Human Study of Novel Peptide Cancer Vaccine
03 Nov 2008 NasVax Commences a Phase I/ IIa Dose-Optimization Clinical Study of VaxiSomeTM-Adjuvanted Influenza Vaccine
31 Oct 2008 Celldex Presents Results from Phase 1 Studies of CDX-1307 with GM-CSF
29 Oct 2008 Nabi Biopharmaceuticals Announces Successful Final Results of NicVAX(r) Immunogenicity Study
29 Oct 2008 Launch of a ph.III clinical trial in adults for Oralair Grasses in the US
27 Oct 2008 Nanoemulsion-Based Intranasal Influenza Vaccine Adjuvant Triggers Robust Immunity Using Significantly Less Antigen
27 Oct 2008 Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two
27 Oct 2008 High-Dose Influenza Vaccine Shows Increased Immune Response Among Adults 65 Years of Age and Older
24 Oct 2008 Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
23 Oct 2008 GlaxoSmithKline and AFFiRiS sign an exclusive licence and option agreement for therapeutic Alzheimer’s disease candidate vaccines
17 Oct 2008 Aeras and Crucell Announce TB Vaccine Clinical Trial in Kenya; Promising Vaccine Candidate Advances to Phase II Safety Study in South Africa
16 Oct 2008 Cell Genesys Announces Termination of VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Based on Outcome of Futility Analysis and Reports Preliminary Analysis of VITAL-2 Trial Results
15 Oct 2008 Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial with Intravenous Delivery of JX-594 Oncolytic Virus
10 Oct 2008 Cyto Pulse, the Karolinska Institute and Uppsala University Hospital Receive Approval from the Swedish Medical Products Agency to Start a Clinical Trial Using a Xenogenic PSA DNA Vaccine
08 Oct 2008 Nventa Presents Findings on Proprietary Toll-Like Receptor 3 (TLR3) Agonist, Poly.ICR, at World Vaccine Congress
07 Oct 2008 Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
07 Oct 2008 Oxford Biomedica Announces FDA Agreement on Revisions for Ongoing Trovax Phase III Trist Study
07 Oct 2008 Bavarian Nordic announces positive mature Phase II results from newly acquired prostate cancer vaccine
07 Oct 2008 Biovest Announces BiovaxID(R) Anti-Cancer Vaccine Prolongs Cancer-Free Survival by 44%
02 Oct 2008 Circassia Initiates Further Phase II Clinical Study Of ToleroMune(R) Anti-Allergy Technology
01 Oct 2008 Apthera Announces Optimal Dose and Schedule of NeuVax for Phase III Clinical Trial in Breast Cancer
30 Sep 2008 VaxInnate's Second Flu Vaccine Candidate Enters Clinical Development; Results Expected in Early 2009
29 Sep 2008 MedImmune Licenses Reverse Genetics Technology to Japan's BIKEN for Use in Influenza Vaccine Development and Production
25 Sep 2008 Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceed Expectations
23 Sep 2008 Pivotal Phase III Pollinex(R) Quattro Ragweed study meets primary efficacy endpoint
23 Sep 2008 Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins
22 Sep 2008 Opexa Announces Top-Line Results from Phase IIb Clinical Trial of Tovaxin(R) for the Treatment of Multiple Sclerosis
21 Sep 2008 Transgene's Therapeutic Vaccine TG4010: Promising Additional Clinical Data in Non Small Cell Lung Cancer Phase IIb Trial
21 Sep 2008 Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
21 Sep 2008 Novartis MF59(R)-adjuvanted vaccine rapidly induces protective antibody levels against diverse strains of avian flu
21 Sep 2008 iBioPharma, Inc. Selects Influenza Vaccine as Its First Clinical Candidate
18 Sep 2008 Multi-Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients
17 Sep 2008 BT Pharma successfully closes EUR 2.8 million (USD 4M) financing round
10 Sep 2008 New Phase II data show Novartis investigational Meningitis B vaccine may also protect infants six months and older
10 Sep 2008 Circassia Achieves Successful Phase II Clinical Results With ToleroMune(R) Anti-Allergy Technology
10 Sep 2008 ImVisioN Therapeutics Starts Phase I Clinical Trial of IVN201 Against Cat Dander Allergy and Raises CHF 4.6 M
03 Sep 2008 Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program
03 Sep 2008 Phase III U.S. Pivotal Study Results on CSL Biotherapies' Afluria Published in Vaccine
28 Aug 2008 Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
28 Aug 2008 Intercell announces initiation of further Phase II clinical trial of V710 an investigational vaccine
27 Aug 2008 Cell Genesys Halts VITAL-2 GVAX Trial in Advanced Prostate Cancer
26 Aug 2008 Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
21 Aug 2008 NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
21 Aug 2008 VaxInnate's M2e Universal Influenza Vaccine Candidate Demonstrates Safety and Immunogenicity in Phase I Clinical Study
21 Aug 2008 VaxInnate's M2e Universal Influenza Vaccine Candidate Demonstrates Safety and Immunogenicity in Phase I Clinical Study
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 50 of 642

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics